Haoxi Health Terminates $80 Million At-The-Market Equity Offering
HAO sits 50% above its 52-week low of $0.82 on light trading volume (0.3× avg).
Summary
Haoxi Health Technology Ltd. has mutually agreed with Aegis Capital Corp to terminate its previously announced $80 million at-the-market equity program, with no shares having been sold under the agreement.
Key Events · Financing and Capital Events · HAO
-
ATM Program Termination
Haoxi Health Technology Ltd. and Aegis Capital Corp mutually terminated the at-the-market equity program established on January 23, 2026.
-
No Shares Sold
The company confirmed that no Class A Ordinary Shares were sold under the $80 million ATM sales agreement prior to its termination.
-
Removes Dilution Overhang
The termination eliminates the potential for significant future equity dilution that the large ATM program represented, which was previously a major concern given its size relative to the company's market capitalization.
Analysis · HAO · Trade & Services
The termination of the $80 million at-the-market (ATM) equity program is a highly positive development for Haoxi Health Technology Ltd. This ATM program, initiated on January 23, 2026, represented a potential dilution exceeding the company's current market capitalization. The fact that no shares were sold before termination removes a significant overhang on the stock, alleviating concerns about substantial future dilution and potential downward pressure on share price. This suggests the company may have found alternative financing or decided against immediate capital raising through equity, which is favorable for existing shareholders.
At the time of this filing, HAO was trading at $1.23 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $73.1M. The 52-week trading range was $0.82 to $2.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.